Deubiquitination of C/EBPβ by FAM63A mediates resistance to glutaminolysis inhibition in MYC-amplified hepatocellular carcinoma
Year: 2026
Type: article
Abstract: Oncogenic MYC amplification drives glutamine addiction in hepatocellular carcinoma (HCC), rendering glutaminase (GLS) a promising therapeutic target. However, MYC-amplified HCC frequently exhibits intrinsic resistance to the GLS inhibitor CB-839, with the underlying adaptive survival mechanisms remaining elusive. Here, we demonstrate that MYC-high HCC cells critically depend on mitofusin 1 (MFN1)-mediated mitochondrial fusion to maintain survival under glutaminolysis inhibition. Furthermore, we show that glutaminolysis inhibition enhances the stability of CCAAT/enhancer-binding protein β (C/EBPβ), which directly activates MFN1 transcription. Mechanistically, MYC-dependent transactivation of FAM63A mediates the deubiquitination of C/EBPβ, specifically suppressing its K48-linked polyubiquitination to enhance C/EBPβ protein stability under glutamine deprivation. Importantly, inhibition of C/EBPβ abrogates MFN1-mediated mitochondrial fusion and triggers autophagic cell death, thereby sensitizing MYC-high HCC cells to GLS inhibition. Our findings identify a novel MYC-FAM63A-C/EBPβ-MFN1 signaling axis that confers adaptive resistance to GLS inhibitors in MYC-high HCC by sustaining mitochondrial fusion. Thus, targeting C/EBPβ represents a promising combinatorial therapeutic strategy to overcome CB-839 resistance in this clinically challenging HCC subtype.
Source: Cell Death and Disease
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,990
OpenAlex ID: W7235167672
